Manganese(II) EOB-Pyclen Diacetate for Liver-Specific MRI

Area of Science:

• Biomedical imaging
• Magnetic Resonance Imaging (MRI)
• Contrast agent development

Background:

• MRI is crucial for diagnosing liver diseases and lesions.
• Gadolinium-based contrast agents (GBCAs) are effective but raise safety concerns due to toxic Gd(III) ion release.
• There is a need for safer, liver-specific MRI contrast agents.

Purpose of the Study:

• To synthesize and evaluate Mn(EOB-PC2A) as a non-gadolinium, liver-specific MRI contrast agent.
• To assess the safety and efficacy of Mn(EOB-PC2A) for liver imaging.
• To provide an alternative to GBCAs for liver MRI.

Main Methods:

• Synthesis of Mn(EOB-PC2A).
• Measurement of relaxivity in DPBS and human serum albumin solutions at 1.5 T.
• Evaluation of hepatocyte uptake and in vivo liver-specific enhancement at a dose of 60 μmol/kg.

Main Results:

• Mn(EOB-PC2A) exhibited relaxivity values of 2.8 mM^-1 s^-1 (DPBS) and 5.9 mM^-1 s^-1 (albumin).
• The agent demonstrated strong hepatocyte uptake with minimal observed toxicity.
• Robust liver-specific enhancement was achieved in vivo at the tested dose.

Conclusions:

• Mn(EOB-PC2A) is a promising manganese-based alternative to GBCAs for liver MRI.
• The agent offers effective liver targeting and enhancement with improved safety profile.
• Further investigation into Mn(EOB-PC2A) could advance liver disease diagnosis.